{"entity":{"id":"nct07743541","kind":"trial","name":"Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy","aka":[],"tldr":"A phase 1/2 trial of TUB-040 run by Gilead Sciences, not yet recruiting.","summary":"Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy is a phase 1/2 interventional study registered as NCT07743541 by Gilead Sciences, with 100 participants planned, started 2026-10. Conditions recorded: Uterine Endometrial Cancer. Interventions recorded: TUB-040 - Dose escalation and TUB-040 - RP2D.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07743541","url":"https://clinicaltrials.gov/study/NCT07743541"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["tub-040"],"companies":["tubulis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07743541","phase":"1/2","setting":"A Multicenter Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the NaPi2B Antibody-Drug Conjugate TUB-040 in Patients With Recurrent or Progressive Uterine Endometrial Cancer After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitor Therapy","sponsor":"Gilead Sciences","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07743541/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"tub-040","kind":"drug","name":"TUB-040","route":"/drugs/tub-040/"}],"company":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"}]}}